drugset / Trial / NCT01539616
A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia
RandomizedParallel-groupTriple-blindTreatment
Summary
ZYH7, a novel peroxisome proliferator-activated receptor (PPAR) alpha agonist, is expected to decrease triglyceride level and also correct dyslipidemia.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-06
- Completion
- 2012-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fenofibrate | Small molecule | 160 mg | Oral |
| Subject | ZYH7 | Unknown | 4 mg | Oral |
| Subject | ZYH7 | Unknown | 8 mg | Oral |
| Subject | ZYH7 | Unknown | 16 mg | Oral |